103 related articles for article (PubMed ID: 20979858)
1. [Clinical significance of expressions of tumor markers in peripheral blood in non-small cell lung cancer].
Qu YM; Liao GQ; Liu PH; Wang HM; Liu L; Li LL; Xie GQ
Zhonghua Yi Xue Za Zhi; 2010 Jul; 90(28):1958-62. PubMed ID: 20979858
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of cytokeratin 19 mRNA expression in peripheral leucocytes in patients with non-small cell lung cancer].
Wang ZH; Kong L; Liu J
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):53. PubMed ID: 17575695
[No Abstract] [Full Text] [Related]
3. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor.
Chen TF; Jiang GL; Fu XL; Wang LJ; Qian H; Wu KL; Zhao S
Lung Cancer; 2007 Apr; 56(1):105-14. PubMed ID: 17166620
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between the mRNA levels of carcinoembryonic antigen and cytokeratin 19 in peripheral blood with staging, treatment response and prognosis in patients with lung cancer].
Wang JH; Zhang SC; Liu ZD; Chen XY; Li CY; Han Y; Ma Y
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Nov; 28(11):773-6. PubMed ID: 16324274
[TBL] [Abstract][Full Text] [Related]
5. Prognostic markers for stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N
Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
[No Abstract] [Full Text] [Related]
6. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
7. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
Jin B; Huang AM; Zhong RB; Han BH
Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitor of apoptosis in lung cancer Livin perioperative clinical research].
Wang LN; Mou J; Zhang YB; Dong P; Diao X; Wang SY; Chen H; Liu YF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Sep; 26(9):889-90. PubMed ID: 20815986
[TBL] [Abstract][Full Text] [Related]
9. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
10. [Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer].
Lazarev SM; Massard Zh; Reshetov AV; Nikolaev GV; Volgin GN; Osipov EV; Lomteva EIu; Nokhrin AV; Kakysheva OE
Vestn Khir Im I I Grek; 2010; 169(1):39-43. PubMed ID: 20387605
[TBL] [Abstract][Full Text] [Related]
11. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
12. Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood.
Yamamoto O; Takahashi H; Hirasawa M; Chiba H; Shiratori M; Kuroki Y; Abe S
Respir Med; 2005 Sep; 99(9):1164-74. PubMed ID: 16085219
[TBL] [Abstract][Full Text] [Related]
13. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
14. [Application of serum surface-enhanced laser desorption/ionization proteomic patterns in distinguishing non-small cell lung cancer patients from healthy people].
Yang SY; Xiao XY; Zhang WG; Sun XZ; Zhang LJ; Zhang W; Zhou B; Yang DC; He DC
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jan; 29(1):31-4. PubMed ID: 16638298
[TBL] [Abstract][Full Text] [Related]
15. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
[TBL] [Abstract][Full Text] [Related]
16. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
17. Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA.
Saito T; Kobayashi M; Harada R; Uemura Y; Taguchi H
Cancer; 2003 May; 97(10):2504-11. PubMed ID: 12733150
[TBL] [Abstract][Full Text] [Related]
18. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1.
de Castro J; Rodríguez MC; Martínez-Zorzano VS; Hernández-Hernández A; Llanillo M; Sánchez-Yagüe J
Cancer Invest; 2008 May; 26(4):407-18. PubMed ID: 18443962
[TBL] [Abstract][Full Text] [Related]
19. Prognostic markers for stage I non-small cell lung cancer.
Ohara G; Satoh H; Hizawa N
Lung Cancer; 2008 Jan; 59(1):137. PubMed ID: 17996327
[No Abstract] [Full Text] [Related]
20. Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer.
Tomita M; Shimizu T; Ayabe T; Yonei A; Onitsuka T
Anticancer Res; 2010 Jul; 30(7):3099-102. PubMed ID: 20683062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
